Breaking Finance News

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) price target increased to $106.00, issued a ratings update earlier today by Zacks Investment Research

Boasting a price of $94.57, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded 0.84% higher on the day. With the last stock price close up 6.87% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. BioMarin Pharmaceutical Inc. has recorded a 50-day average of $95.46 and a two hundred day average of $89.02. Volume of trade was down over the average, with 799,720 shares of BMRN changing hands under the typical 1,754,740

Indicating a possible upside of 0.12%, Zacks Investment Research bumped up the target of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $106.00

On 8/24/2016, Vetr Inc. released a statement for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) bumped up the target price from $0.00 to $111.64 that suggested an upside of 0.17%.

Performance Chart

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

With a total market value of $0, BioMarin Pharmaceutical Inc. has with a one year low of $62.12 and a one year high of $118.48 .

A total of 20 equity analysts have released a ratings update on BMRN. Six equity analysts rating the company a strong buy, eleven equity analysts rating the company a buy, two equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $116.10.

Brief Synopsis About BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with mucopolysaccharidosis VI (MPS VI). Kuvan is a synthetic oral form of 6R-BH4 indicated for patients with phenylketonuria (PKU).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *